Skip to content
Menu

Iambic Therapeutics Q3 EPS $(8.52) Misses $(0.72) Estimate, Sales $11.351M Miss $15.133M Estimate

Benzinga Newsdesk 1 day ago

NewsEarningsEarnings Misses

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Iambic Therapeutics (NASDAQ:IAM) reported quarterly losses of $(8.52) per share which missed the analyst consensus estimate of $(0.72) by 1083.33 percent. This is a 62.6 percent decrease over losses of $(5.24) per share

Iambic Therapeutics (NASDAQ:IAM) reported quarterly losses of $(8.52) per share which missed the analyst consensus estimate of $(0.72) by 1083.33 percent. This is a 62.6 percent decrease over losses of $(5.24) per share from the same period last year. The company reported quarterly sales of $11.351 million which missed the analyst consensus estimate of $15.133 million by 24.99 percent. This is a 141.92 percent increase over sales of $4.692 million the same period last year.

Read at benzinga.com